Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

18/06/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.14%, closing at 51564.7 points; the Nasdaq Composite rose by 1.91%, closing at 26517.93 points; the S&P 500 Index rose by 1.08%, closing at 7500.58 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

FreeCast, Inc. Class A: Overnight gain 56.7%, Surges Amid Strategic Partnerships with DIRECTV and Starlink Business

FreeCast, Inc. was incorporated on June 21, 2011, and is domiciled in the state of Florida. The company operates as an entertainment content discovery, aggregation, and management services provider, with its core business focused on delivering SmartGuide digital interactive technology solutions to consumers. This proprietary technology is designed to consolidate and organize the increasingly fragmented online media landscape, functioning as a digital equivalent to traditional television program guide systems, thereby providing users with a unified digital media navigation platform.

FreeCast, Inc. Class A (CAST) shares surged 56.7% on Tuesday, ranking fourth among top gainers in U.S. markets, driven by two significant strategic partnership announcements that substantially enhanced the streaming technology company's growth prospects. The company announced an expanded collaboration with DIRECTV, integrating DIRECTV streaming services into its residential business and Platform-as-a-Service ecosystem. This partnership enables service delivery through existing channels without satellite dish installation, creating immediate recurring revenue opportunities for FreeCast, Inc. Class A (CAST). Additionally, the company secured a new dealer agreement with Starlink Business, expanding enterprise services into multi-dwelling units, hospitality, and healthcare markets. From a technical perspective, CAST shares were previously oversold with an RSI of 27.38. MACD indicators showed declining pressure had eased prior to the news-driven rally, providing technical support for the rebound. These strategic partnerships triggered speculative buying interest, significantly boosting the company's market valuation and future revenue potential.

Butterfly Network, Inc. Class A: Overnight gain 55.9%, Surges Amid Strategic Partnership and Ultrasound Technology Platform Breakthrough

**Butterfly Network, Inc. Leverages Proprietary Semiconductor Technology to Democratize Medical Imaging** Butterfly Network, Inc., incorporated on February 4, 2020, and domiciled in Delaware, has successfully developed the world's first handheld, single-probe, whole-body ultrasound system through its proprietary semiconductor technology platform. The company is strategically positioned to advance the democratization of medical imaging technology, with a mission to promote global healthcare equity by extending medical support to approximately 4.7 billion people worldwide who currently lack access to ultrasound services. The company's flagship product, Butterfly iQ, is classified as a prescription medical device and is exclusively intended for use by professionally trained and appropriately credentialed healthcare practitioners. This regulatory positioning underscores the company's commitment to maintaining clinical standards while expanding accessibility to advanced imaging capabilities. Through its innovative technology platform, Butterfly Network is addressing a significant global healthcare gap, positioning itself at the intersection of semiconductor innovation and medical device manufacturing to serve underserved populations in the global healthcare market.

Butterfly Network, Inc. Class A (BFLY) shares surged 55.9% following significant breakthroughs in ultrasound imaging technology. The company's collaborative development agreement with Midjourney marks a strategic transformation from traditional single-probe ultrasound device manufacturer to technology platform provider. The newly developed tomographic imaging prototype integrates 40 Butterfly ultrasound chip imaging modules per system, demonstrating substantial technological advancement and product innovation capabilities. This partnership opens new revenue streams through technology licensing while validating the application potential of Butterfly's ultrasound chip technology in sophisticated medical imaging equipment. The company indicated future products will incorporate additional imaging modules, highlighting the robust scalability of its technology platform. This modular, platform-based development approach has enhanced investor confidence in Butterfly Network's long-term growth prospects within the medical imaging market, driving the dramatic single-day stock surge.

Kardigan: Overnight gain 37.5%, Surges Following Successful IPO Pricing Amid Strong Market Demand for Cardiovascular Therapies

**Kardigan Corporation Emerges as Clinical-Stage Biopharmaceutical Company Targeting Cardiovascular Precision Medicine** Kardigan Corporation, incorporated in Delaware in August 2023, operates as a clinical-stage biopharmaceutical company specializing in precision therapeutics for cardiovascular diseases. The company is dedicated to developing innovative pharmaceutical solutions that address the underlying pathophysiology of specific cardiovascular conditions, with a strategic focus on disease areas currently lacking approved therapeutic interventions. The company employs a parallel development strategy to advance multiple targeted cardiovascular therapeutic programs simultaneously. Kardigan's current pipeline comprises three core assets in late-stage clinical development: Danicamtiv, Ataciguat, and Tonlamarsen, all targeting indications with significant unmet medical needs and no currently approved treatment options. The company's management team brings extensive domain expertise in cardiovascular medicine, leveraging innovative drug development methodologies in conjunction with proprietary data analytics capabilities through its Prolaio platform to drive efficient research and development execution. Kardigan's approach to cardiovascular drug development emphasizes precision medicine principles, focusing on addressing the fundamental etiological mechanisms of disease rather than providing symptomatic management of late-stage cardiovascular manifestations. This strategy positions the company to deliver transformative therapeutic solutions that target the root causes of cardiovascular pathology, potentially offering definitive treatment options for patients with cardiovascular diseases.

Kardigan (KARD) stock surge reflects multiple positive catalysts converging simultaneously. The company successfully completed a $400 million IPO at $16 per share, expanding from the initially planned $350 million offering due to robust market demand. As a clinical-stage precision therapeutics company focused on cardiovascular disease drug development, Kardigan (KARD) addresses significant unmet medical needs in areas lacking approved treatments, presenting substantial commercial value potential. The company's pipeline features three late-stage clinical programs: Danicamtiv, Ataciguat, and Tonlamarsen, complemented by its proprietary Prolaio platform technology, providing investors with compelling growth prospects. The high-profile underwriting syndicate led by JPMorgan Chase and Jefferies further validates market confidence in Kardigan's (KARD) quality and potential. This combination of successful capital raising, promising therapeutic pipeline, and prestigious banking partnerships positions the company favorably for future development in the cardiovascular therapeutics market.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team. Risk and Disclaimer: The content provided above is solely for informational purposes and does not represent the views or positions of Sahm Platform. While we strive for accuracy, we cannot guarantee the authenticity or completeness of the information contained in the provided content. We strongly recommend that investors consult with a qualified investment advisor when deemed necessary. Sahm Platform neither provides investment advice nor makes any representations or warranties concerning the accuracy, reliability, or completeness of the information in the content provided above. By using Sahm Platform, you acknowledge that you have read, understood, and agreed to the terms set forth in this disclaimer.